Background: Gastric cancer often presents in a metastasized stage. We conducted a population-based study to evaluate trends in systemic treatment and survival of metastatic noncardia gastric cancer.
introduction
Due to lack of early symptoms, gastric cancer often presents in a metastasized stage, characterized by poor survival [1, 2] . Several studies have shown that palliative chemotherapy is superior to 'best supportive care' for selected patients, in terms of prolonged survival, reduction of disease-related symptoms and improved quality of life [3] . Although most studies were small and of moderate methodological quality, this evidence has led to the implementation of palliative chemotherapy into national guidelines on the treatment of gastric cancer [4] [5] [6] . The NCCN guideline Gastric Cancer for instance, recommends chemotherapy with a two or three drug regimen for patients with metastatic gastric cancer [5] . The Dutch guideline recommends a combination regimen with epirubicine, a platinum derivative and a fluoropyrimidine as first-line palliative treatment as well [4] .
A recent population-based Dutch study showed that adherence to national guidelines for resectable gastric cancer was suboptimal, only 47% and 56% of the patients received recommended preoperative and postoperative chemotherapy [7] . Daily practice data on the prescription of palliative chemotherapy for patients' metastatic gastric cancer are scarce. In this study, we examined trends in the use of chemotherapy for patients' metastatic (noncardia) gastric cancer, diagnosed between 1990 and 2011 in the southern part of the Netherlands. In addition, we assessed to which extent patient-and tumorrelated factors influenced the administration of chemotherapy and if there was any variation in prescription between 10 community hospitals. Finally, we evaluated trends in overall survival for patients with metastatic gastric cancer.
methods data collection
Data were obtained from the Eindhoven Cancer Registry in the Netherlands which collects data on diagnosis, staging and treatment of all patients with newly diagnosed cancer. Registration takes place within 6-9 months after diagnosis by specially trained administrators. The Eindhoven Cancer Registry serves ∼2.4 million inhabitants, about 15% of the Dutch population. It contains data of 6 pathology departments, the medical records of 10 community hospitals and 2 radiation therapy institutes.
Patients diagnosed with noncardia adenocarcinoma of the stomach between 1 January 1990 and 31 December 2011 were included. Topography and morphology were coded according to the International Classification of Disease. The following morphology codes were used to classify tumors as adenocarcinoma 8140-8145, 8210, 8211, 8255, 8260-8263, 8480-8481, 8490, 8560 and 8570 (other morphologies were excluded or did not occur during the study period). Tumors were classified according to the TNM classification and staged following the recommendations of the International Union Against Cancer in the respective period (4th-7th edition). Clinical stage was used in case of missing pathological stage. If tumor stage was unknown it was classified as X.
Since 1993, clinically relevant comorbidities were registered according to a slightly modified version of the Charlson comorbidity index. The social economic status (SES) of individual patients was defined at neighborhood level using postal codes (17 households on average), combining mean household income and mean value of the house/apartment. Postal codes were assigned to three SES categories: low (1st-3rd deciles), intermediate (4th-7th) and high (8th-10th) [8] .
Vital status of patients at 1 January 2012 was assessed through linkage with civil municipal registries and the central Bureau for Genealogy, which collects data on all deceased Dutch Citizens. Survival was calculated based on all-cause mortality.
statistical analysis
Differences in the prescription of systemic chemotherapy between periods of diagnosis, hospitals of diagnosis and other subgroups were tested by means of a χ 2 test. The independent influence of hospital, patient and tumor characteristics on the administration of palliative chemotherapy was evaluated by means of a logistic regression analyses. Survival time was defined as the time from diagnosis to death; patients still alive at January 2012 were censored. A log-rank test was carried out to evaluate significant differences between survival curves. To discriminate independent risk factors for death, a multivariable proportional hazard regression analysis was used.
All tests were two-sided and considered statistically significant if P-values <0.05. SAS Statistical software (version 9.3) was used to perform all analyses.
results
Patients with noncardia gastric cancer diagnosed between 1 January 1990 and 31 December 2011 in the southern part of the Netherlands were included. The final cohort consisted of 4797 patients, 2865 men (60%) and 1932 women (40%) with a median age of 72 years (range 13-100) at time of diagnosis. The incidence rate of noncardia gastric cancer in the above mentioned region decreased in the last two decades, from 27 per 100 000 in 1990 to 13 per 100 000 in 2010. A significant proportion of patients with noncardia gastric cancer presented with metastatic disease at time of diagnosis. In total, 40% of the patients with metastatic gastric cancer presented with liver metastases whether or not with concomitant metastases elsewhere, and 44% with peritoneal dissemination. The proportion of patients presenting with metastatic disease at time of diagnosis increased from 24% in 1990 to 44% in 2011 (P < 0.0001).
Overall, the proportion of patients with metastatic gastric cancer receiving palliative chemotherapy increased from 5% in 1990 to 36% in 2011 ( Figure 1 ). A remarkable increase was seen after 2006. Table 1 shows the odds of receiving chemotherapy for patients with metastatic gastric cancer adjusted for age, gender, SES, comorbidity, histologic subtype, tumor grade, presence and location of distant metastasis, period and hospital of diagnosis. After adjustment, elderly patients (70-79 and ≥80 years), patients with concomitant comorbidity, those with multiple distant metastases or linitis plastica received chemotherapy less often. In contrast, chemotherapy was administered more frequently to young patients (<60 years) and patients with a higher SES. Furthermore, a large interhospital variation was seen in the proportion of patients receiving chemotherapy, varying from 9% to 27%.
No improvement in overall survival was observed in the last two decades (Figure 2 ). The median survival for patients with metastatic gastric cancer remained 15-17 weeks (P = 0.10). The overall survival for patients not treated with chemotherapy worsened. Initially, the median survival for untreated patients with metastatic gastric cancer was 16 weeks; in 2008-2011, the median overall survival was only 9 weeks (P < 0.001). For patients treated with chemotherapy, the overall survival remained stable between the 32-37 weeks (P = 0.39). In a multivariate model, chemotherapy was positively associated with survival. After adjustment, male gender, a poor or undifferentiated tumor, the presence of liver or multiple metastases were negative prognostic factors (Table 2) . discussion An increasing percentage of patients with gastric cancer is diagnosed with metastatic disease. Although the proportion of patients treated with palliative chemotherapy increased drastically, it did not lead to an increase in the population-based overall survival in patients with metastatic gastric cancer. The proportion of patients presenting with metastatic disease at time of diagnosis increased from 25% in 1990 to 44% in 2011. Improved staging procedures have played an important role. The modern improved computed tomography scan (CT) sometimes in combination with positron emission tomography (PET) scan further enhanced the diagnostic process [9, 10] . These evolving technologies presumably led to stage migration by earlier and increased detection of distant metastases, mostly occurring in liver and peritoneum [10] . In addition, altered, more aggressive biological behavior of gastric cancer, could also be related to the rising proportion of patients presenting with metastatic disease. Nevertheless, to our knowledge no data are available on this subject and further investigation is needed.
Several randomized trials have shown that systemic chemotherapy can reduce disease related symptoms and improve median survival, from ∼4-11 months in selected patients with metastatic gastric cancer [3] . This benefit of palliative chemotherapy over best supportive care alone was already reported in several studies in the early nineties [3] . The last Cochrane review on chemotherapy for advanced and metastatic gastric cancer concluded that combination regimens including 5-FU or capecitabine and oxaliplatin or cisplatin, with or without an anthracycline, or docetaxel and irinotecan-based regimens can be considered as reasonable treatment options [3] . The newly introduced agents, oxaliplatin, docetaxel and irinotecan have an altered and often a more favorable toxicity profile, but provide similar overall survival as previous studied agents. Despite modest changes in the treatment of metastatic gastric cancer the administration of palliative chemotherapy increased drastically, in particular after 2006. In 1990, 5% of patients with metastatic gastric cancer was treated with palliative chemotherapy. Gradually, the percentage increased to 20% in 2006, and even 36% in 2011.
In 2005, Cunningham published the results of the REAL-2 trial in which capecitabine and oxaliplatin were established as equal substitutes of 5-fluorouracil and cisplatin in triplet regimens for the treatment of metastatic gastric cancer [11] . Furthermore, in 2006, Cunningham et al. [12] published the MAGIC trial in which they demonstrated that perioperative chemotherapy with a regimen of ECF significantly improved progression-free and overall survival for patients with resectable gastric cancer. Presumably, the growing experience with combination chemotherapy in the treatment of gastric cancer has led to a stronger increase in the administration of palliative chemotherapy the recent years. The current study demonstrates that patients with a lower socioeconomic status (SES), advanced age and comorbidity were less likely to be treated with chemotherapy. In addition, tumor-related factors such as metastases in multiple organs and linitis plastica were adversely related to the prescription of chemotherapy as well. The increased hazard of death for patients with linitis plastica, although of borderline significance, suggests that this is a negative prognostic factor. The presence of metastases in multiple organs was not associated with an increased risk of dying compared with patients with liver metastases only. However, due to the population-based nature of our data, we do not know to which extent above mentioned conditions had impact on performance status, nutritional status etc. and in this manner influenced the prescription of chemotherapy. The reluctance to prescribe chemotherapy for elderly patients has already been described in previous studies [13, 14] . Also treatment selection according to SES has frequently been reported for curative cancer treatments [15] [16] [17] . However, only a few studies have reported the effect of SES on treatment decisions in the palliative setting. Recently, Swedish investigators established high education level as an important socioeconomic variable, associated with more intensive treatments [18] . In a multivariate model adjusting for case mix, a marked hospital variation was found in the prescription of palliative chemotherapy, varying between 9% and 27%. Decisions concerning the use of chemotherapy in patients with metastatic cancer are complex [19, 20] . A recent study found that the physicians' individual treatment recommendations were strongly influenced by the amount of experience and their judgment about the benefit of the treatment and biological age of the patient [20] .
Despite the increased prescription of palliative chemotherapy and the presumed stage migration, the overall survival of all patients with metastatic gastric cancer did not change over time. Median survival of patients with metastatic disease remained poor, between 15 and 17 weeks. As expected, poor/ undifferentiated tumors and the presence of multiple metastases were associated with poor survival [21] . Consistent with previous reports, in case of single-site metastases, dissemination to the liver was identified as an independent adverse prognostic factor as well [22] . In addition to tumor-related prognostic factors, there was a significant effect of sex on overall survival. We found that women with metastatic gastric cancer had a better survival compared with their male counterparts. According to the study of Yang et al., using the data of the SEER registry, this difference was associated to race and limited to African Americans and White patients. This race specific gender difference in survival is possibly related to sex hormones, their receptor expression and possible interaction with HER2neu receptor pathways [23] . Our data do not confirm the [24] . Survival of patients treated with systemic chemotherapy the last two decades remained stable between 32 and 37 weeks. This may reflect the lack of a major breakthrough in the efficacy of the cytotoxic drugs used in the treatment of gastric cancer. The survival of patients not treated with palliative chemotherapy worsened in the last two decades, from an initial survival of 16 weeks to a survival of only 9 weeks in the most recent period. This is probably due to selection bias, as patients who are medically fit are more likely to be treated with palliative chemotherapy. As a result of the increased administration of chemotherapy, the oldest and/or most frail patients remain untreated. Due to the population-based nature of our data, detailed information on the patients' health and nutritional status were unfortunately not available. Also information concerning established prognostic factors as body mass index, ECOG performance status of the patient and symptoms like ascites are lacking in our database [25, 26] . These factors influence prognosis and presumably the administration of chemotherapy in daily practice.
In conclusion, the increased administration of chemotherapy for patients with metastatic gastric cancer did not lead to an increased population-based overall survival. A subgroup of patients might benefit from palliative chemotherapy, but more research is necessary to establish prognostic and in particular predictive factors for patients with metastatic gastric cancer.
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